- Home
- BMRN
as 06-20-2025 4:00pm EST
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 12.1B | IPO Year: | 1999 |
| Target Price: | $93.43 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.71 | EPS Growth: | 152.82 |
| 52 Week Low/High: | $52.93 - $94.85 | Next Earning Date: | 08-04-2025 |
| Revenue: | $2,950,227,000 | Revenue Growth: | 19.36% |
| Revenue Growth (this year): | 12.23% | Revenue Growth (next year): | 9.99% |
Stock Insider Trading Activity of BioMarin Pharmaceutical Inc. (BMRN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burkhart Erin | BMRN | GVP, Chief Accounting Officer | May 19 '25 | Sell | $59.31 | 1,786 | $105,927.66 | 14,173 | |
| Hubbard Cristin | BMRN | EVP, Chief Commercial Officer | May 2 '25 | Sell | $64.92 | 273 | $17,723.16 | 32,700 |
Latest BioMarin Pharmaceutical Inc. News
BMRN Breaking Stock News: Dive into BMRN Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 hours ago
Does The Market Have A Low Tolerance For BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Fundamentals?
StockStory
2 days ago
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Think Twice About
Insider Monkey
6 days ago
Jim Cramer on BioMarin: “I Don’t Think It Works Now”
Zacks
10 days ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Argus Research
10 days ago
BMRN: Raising target price to $63.00
Zacks
12 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Motley Fool
16 days ago
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
StockStory
16 days ago
1 Mid-Cap Stock with Exciting Potential and 2 to Avoid
Compare BMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMRN BioMarin Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.